Compare RUN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | VCEL |
|---|---|---|
| Founded | 2007 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2015 | 1996 |
| Metric | RUN | VCEL |
|---|---|---|
| Price | $6.97 | $40.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | $14.64 | ★ $59.71 |
| AVG Volume (30 Days) | ★ 7.4M | 488.6K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | 60.00 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $858,578,000.00 | $276,259,000.00 |
| Revenue This Year | $4.94 | $21.71 |
| Revenue Next Year | $3.38 | $16.86 |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | 12.97 | ★ 16.45 |
| 52 Week Low | $7.17 | $28.95 |
| 52 Week High | $21.95 | $49.32 |
| Indicator | RUN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.79 | 50.37 |
| Support Level | N/A | $38.19 |
| Resistance Level | $8.95 | $41.06 |
| Average True Range (ATR) | 0.34 | 1.30 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 7.17 | 57.50 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.